Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$1.84
+0.3%
$2.00
$1.41
$2.79
$83.18M1.4666,881 shs9,071 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$11.45
-8.3%
$10.28
$4.11
$28.68
$82.16M2.97173,240 shs113,360 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$12.75
-1.9%
$13.26
$1.27
$15.85
$20.88M1.212,149 shs1,741 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.84
$1.49
$1.02
$7.89
$104.13M0.97408,742 shs231,710 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
+0.27%-5.90%-13.85%+8.58%+1.94%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-8.25%-17.09%-6.53%+118.10%+56,027.45%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-1.92%-2.49%-4.76%+2.82%+858.65%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.00%+21.85%+8.88%+48.39%-69.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2.289 of 5 stars
3.55.00.00.00.60.80.0
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.3749 of 5 stars
3.54.00.00.03.31.70.6
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1.1444 of 5 stars
0.03.00.00.02.91.70.6
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.643 of 5 stars
3.51.00.00.02.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entera Bio Ltd. stock logo
ENTX
Entera Bio
3.00
Buy$10.00444.96% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00432.75% Upside
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80323.91% Upside

Current Analyst Ratings Breakdown

Latest FNCH, FBRX, ENTX, and TCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
5/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
5/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$180K463.34N/AN/A$0.23 per share7.98
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$4.42M23.55N/AN/A$4.26 per share0.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$127.50M-$1.09N/AN/AN/A-2,974.08%-55.76%-36.56%8/11/2025 (Estimated)

Latest FNCH, FBRX, ENTX, and TCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.11N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/12/2025Q1 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million
5/9/2025Q1 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.07-$0.06+$0.01-$0.06N/A$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/A
13.07
13.07
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.15
8.55
8.55

Institutional Ownership

CompanyInstitutional Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
14.11%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
10.38%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2045.45 million40.73 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million54.13 millionNot Optionable

Recent News About These Companies

Tscan Therapeutics Inc News (TCRX) - Investing.com
Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)
TScan Therapeutics appoints Camiolo as SVP, Market Access
TScan Therapeutics assumed with an Overweight at Morgan Stanley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entera Bio stock logo

Entera Bio NASDAQ:ENTX

$1.84 +0.01 (+0.27%)
Closing price 07/10/2025 03:50 PM Eastern
Extended Trading
$1.84 +0.01 (+0.54%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$11.45 -1.03 (-8.25%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$11.46 +0.01 (+0.04%)
As of 07/10/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$12.75 -0.25 (-1.92%)
As of 07/10/2025 01:49 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.84 0.00 (0.00%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.90 +0.06 (+3.53%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.